The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.
PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib
Open accessAbstract
Background KRAS is a frequently mutated oncogene in human cancer. Clinical studies on the covalent inhibitors of the KRAS G12C mutant have reported promising results. However, primary and acquired resistance may limit their clinical use.Methods Sotorasib-resistant cell lines were established. We explored the signalling pathways activated in these resistant cell lines and their roles in sotorasib resistance.Results The resistant cells exhibited increased cell-matrix adhesion with increased levels of stress fibres and focal adherens. p21-activated kinases (PAKs) were activated in resistant cells, which phosphorylate MEK at serine 298 of MEK and serine 338 of c-Raf to activate the mitogen-activated protein kinase pathway. The PAK inhibitors FRAX597 and FRAX486 in synergy with sotorasib reduced the viability of KRAS G12C mutant cancer cells. Furthermore, the PI3K/AKT pathway was constitutively active in sotorasib-resistant cells. The overexpression of constitutively activated PI3K or the knockdown of PTEN resulted in resistance to sotorasib. PI3K inhibitor alpelisib was synergistic with sotorasib in compromising the viability of KRAS G12C mutant cancer cells. Moreover, PI3K and PAK pathways formed a mutual positive regulatory loop that mediated sotorasib resistance.Conclusions Our results indicate that the cell-matrix interaction-dependent activation of PAK mediates resistance to sotorasib through the activation of MAPK and PI3K pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study of sotorasib-resistant KRAS G12C cancer cells identified constitutive activation of the PI3K/AKT pathway [111].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [111]
In the citing paper
“Overexpression of the constitutively active PIK3CA mutants or knockdown of PTEN reduced sotorasib sensitivity, and PI3K inhibition by alpelisib significantly increased sotorasib sensitivity [111].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [111]
In the citing paper
“The FAK/SRC axis is responsible for elevated activity of p21 activated kinase (PAK), which activates CRAF and MEK, promoting sotorasib resistance in KRAS G12C cancer cells [111].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [111]
In the citing paper
“PI3K or AURKA inhibition has also been found to increase the efficacy of HRS4642. 23-26”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [26]
In the citing paper
“The results indicated that drugs inhibiting Aurora kinase A (Ly3295668) and Pi3k (alpelisib) prominently synergized with HRS-4642 (Figures S2E and S2G), consistent with previous reports in KRAS G12C-targeted therapy. 23-26”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [26]
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Combination index (CI) values of <1, 1, and >1 indicate synergism, an additive effect, and antagonism, respectively [18].”
BackgroundAKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 1×
“Alpelisib is a recently approved PI3K inhibitor for the treatment of PI3K-mutated, oestrogen receptor-positive, and Her-2 negative breast cancer [28].”
BackgroundK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849 · cited 1×
“observed in 46 of 124 lung cancer patients, which included 4 patients with a complete response and 42 patients with a partial response [10].”
BackgroundMitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity
Weinberg, F., Hamanaka, R., Wheaton, W. W., Weinberg, S., Joseph, J., Lopez, M., Kalyanaraman, B., Mutlu, G. M., Budinger, G. R. S., & Chandel, N. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003428107 · Cited by 1,742 · cited 1×
“Consistent with the role of KRAS in mitochondrial metabolism [19], genes involved in the citric acid cycle and oxidative phosphorylation were downregulated in sotorasib-resistant cells (Supplementary Fig.”
BackgroundKRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
A brain serine/threonine protein kinase activated by Cdc42 and Rac1
Manser, E., Leung, T., Salihuddin, H., Zhao, Z.-S., & Lim, L. (1994) · Nature · doi:10.1038/367040a0 · Cited by 1,538
Research works printed but not linked: 1
- Rodenhuis S. Ras and human tumors. Semin Cancer Biol. 1992;3:241–7.
Cited by
PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment
Jiang, M., Zhang, K., Zhang, Z., Zeng, X., Huang, Z., Qin, P., Xie, Z., Cai, X., Ashrafizadeh, M., Tian, Y., et al. (2025) · MedComm · doi:10.1002/mco2.70295 · Cited by 234
Zhou, C., Li, C., Luo, L., Li, X., Jia, K., He, N., Mao, S., Wang, W., Shao, C., Liu, X., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.001 · Cited by 102
KRAS G12C inhibitor combination therapies: current evidence and challenge
Miyashita, H., Kato, S., & Hong, D. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1380584 · Cited by 106
Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer
Tufail, M., Wan, W., Jiang, C., & Li, N. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111055 · Cited by 80
Response and Resistance to RAS Inhibition in Cancer
Ebright, R. Y., Dilly, J., Shaw, A. T., & Aguirre, A. J. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0349 · Cited by 83
Metadata
- Authors
- Chan, C.-H., Chiou, L.-W., Lee, T.-Y., Liu, Y.-R., Hsieh, T.-H., Yang, C.-Y., & Jeng, Y.-M.
- Affiliations
- National Taiwan University (TW)
- Taipei Medical University (TW)
- Corresponding author
- Yang, Ching-Yao
- Jeng, Yung-Ming
- Venue
- British Journal of Cancer
- Published
- 2022-11-01
- Volume
- 128
- Issue
- 1
- Pages
- 148-159
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC9814377
- OpenAlex
- W4307975982
- Semantic Scholar
- d1866750e6b5ca0f5dcfd3ea23749bd3289b94ee
- Cited by
- 56
- References
- 42
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 15 · 2023: 11
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- British Journal of Cancer (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology, Taiwan (109-2314-B-002-084, 110-2314-B-002-173)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- KRAS G12C, sotorasib, drug resistance, p21-activated kinase, PI3K/Akt signaling, MEK phosphorylation, Raf-1, MAPK signaling, cell-matrix adhesion, stress fibers, focal adhesions, PTEN, alpelisib, combination therapy, KRAS inhibitor resistance
- MeSH terms
- Humans, Lung Neoplasms, Mutation, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib. https://app.cochat.ai/papers/10.1038/s41416-022-02032-w
- The paper
- Chan, C.-H., Chiou, L.-W., Lee, T.-Y., Liu, Y.-R., Hsieh, T.-H., Yang, C.-Y., & Jeng, Y.-M. (2023). PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib. British Journal of Cancer. https://doi.org/10.1038/s41416-022-02032-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.